Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed...
Main Authors: | Alfredo García-Layana, Marta S. Figueroa, Luis Arias, Javier Araiz, José María Ruiz-Moreno, José García-Arumí, Francisco Gómez-Ulla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel García-Campos, Jordi Monés, Enrique Cervera, Felix Armadá, Roberto Gallego-Pinazo |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2015/412903 |
Similar Items
-
A Delphi Study to Detect Deficiencies and Propose Actions in Real Life Treatment of Neovascular Age-Related Macular Degeneration
by: Alfredo García-Layana, et al.
Published: (2014-01-01) -
Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
by: Hüseyin Dündar, et al.
Published: (2014-10-01) -
Do Nutritional Supplements Have a Role in Age Macular Degeneration Prevention?
by: Maria D. Pinazo-Durán, et al.
Published: (2014-01-01) -
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
by: Dervenis N, et al.
Published: (2016-06-01) -
Clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration
by: Ling-Jun Wei, et al.
Published: (2017-12-01)